Gilead Sciences is withdrawing the approval status of sacituzumab govitecan for bladder cancer treatment. The withdrawal is reportedly due to a negative trial, which showed a lack of survival benefit for the drug, also known as Trodelvy, in metastatic urothelial cancer. The drug's approval for bladder cancer, specifically urothelial carcinoma, is being withdrawn in the US.